Discover
ALEC
Alector, Inc.
2.01
2 x 1.48
2 x 2.50
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
2.01 +0.00 (0.00%)
| Ytd | 28.85% | |
| 1y | 41.55% |
1.96
day range
2.06
1.09
52 week range
3.40
| Open | 1.99 | Prev Close | 2.01 | Low | 1.96 | High | 2.06 | Mkt Cap | 223.16M |
| Vol | 365.35K | Avg Vol | 716.98K | EPS | -1.19 | P/E | N/A | Forward P/E | -1.25 |
| Beta | 0.66 | Short Ratio | 3.92 | Inst. Own | 95.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 2.05 | 200-d Avg | 2.04 | 1yr Est | 5.51 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.53 | -0.43 | 0.1 | 18.87% |
| 2024-08-07 | 2024-06 | -0.49 | -0.4 | 0.09 | 18.37% |
| 2024-08-07 | 2024-06 | -0.49 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.48 | -0.38 | 0.1 | 20.83% |
| 2024-05-08 | 2024-03 | -0.48 | N/A | N/A | N/A |
| 2024-02-27 | 2023-12 | -0.8 | -0.49 | 0.31 | 38.75% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-16 | Stifel | Downgrade | Buy | Hold |
| 2024-11-26 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| 2024-11-26 | BTIG | Upgrade | Buy | Buy |
| 2024-11-26 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2024-11-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-17 | Cantor Fitzgerald | Upgrade | Overweight |
Profile
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-11 | GAROFALO ELIZABETH A. | Director | 61.25K | Stock Award(Grant) |
| 2024-12-01 | GRASSO MARC | Chief Financial Officer | 330.65K | Sale |
| 2024-08-11 | HAMMOND PAULA | Director | 60.21K | Sale |
| 2024-12-01 | KENKARE-MITRA SARASWATI | Officer | 565.22K | Sale |
| 2024-06-11 | LAVIGNE LOUIS J JR | Director | 81.26K | Stock Award(Grant) |
| 2024-12-01 | ROMANO GARY | Officer | 349.28K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 14.60M | 27.00M | 14.90% |
| 2024-09-29 | Blackrock Inc. | 9.35M | 17.30M | 9.55% |
| 2024-09-29 | Vanguard Group Inc | 5.46M | 10.09M | 5.57% |
| 2024-09-29 | Deep Track Capital, Lp | 4.63M | 8.57M | 4.73% |
| 2024-09-29 | Morgan Stanley | 4.36M | 8.06M | 4.45% |
| 2024-09-29 | JP Morgan Chase & Company | 2.73M | 5.05M | 2.79% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Growth Company Fund | 3.64M | 6.73M | 3.71% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 3.54M | 6.54M | 3.61% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.37M | 4.38M | 2.42% |
| 2024-10-30 | iShares Russell 2000 ETF | 2.10M | 3.88M | 2.14% |
| 2024-09-29 | JP Morgan Small Cap Growth Fund | 1.51M | 2.79M | 1.54% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 1.27M | 2.35M | 1.30% |